On December 26, 2019 was signed bilateral cooperation Memorandum between L. Sakvarelidze National Center for Disease Control and Public Health and EGIS Pharmaceuticals PLC Representation in Georgia.
The main purpose of the Memorandum is to develop bilateral close cooperation between the parties on determination of the prevalance of hyperuricemia among the high risk population. The Memorandum envisages the active involvement of the Company and the Center staff in the processes under this Memorandum, as well as the jointly planned work of the parties.
Hyperuricemia - raised serum uric acid, is the condition closely associated with gout. Hyperuricemia has also been reported as an independent risk factor for coronary heart disease, the metabolic syndrome, diabetes, stroke and incident mortality.
The uric acid levels in blood usually are higher in men than in women, although uric acid levels in blood tend to increase with age. The prevalence and incidence of hyperuricemia in the worldwide population has increased significantly over the last 40 years.
Uric acid levels are also significantly associated with age, BMI, blood pressure, alcohol and the use of antihypertensive therapy. Considering the growing incidence of obesity and metabolic syndrome worldwide and the potential link between hyperuricemia and cardiovascular complications, more emphasis should be put on the evolving prevalence of hyperuricemia.